Additional news is supposed to be coming out this month, October 2016.
“TheravaxHSV is a therapeutic vaccination series. By retraining the immune system to better control herpes simplex virus (HSV), TheravaxHSV offers sufferers the possibility of reducing their genital herpes symptoms. Phase 1 Clinical Trials of TheravaxHSV are imminent.”
ProfavaxHSV is a prophylactic vaccination series that offers the opportunity for recipients to acquire protective immunity against HSV-1 or HSV-2, and thus protect themselves against the risk of acquiring oral or genital herpes. Phase 1 Clinical Trials of ProfavaxHSV will begin after the TheravaxHSV vaccine has completed Phase 1 safety trials.”